Androgenetic alopecia, or male/female pattern baldness, is the most common type of progressive hair loss disorder. The aim of this study was to review recent advances in non-surgical treatments for androgenetic alopecia and identify the most effective treatments. A network meta-analysis (NMA) was conducted of the available literature of the six most common non-surgical treatment options for treating androgenetic alopecia in both men and women; dutasteride 0.5 mg, finasteride 1 mg, low-level laser therapy (LLLT), minoxidil 2%, minoxidil 5% and platelet-rich plasma (PRP). Seventy-eight studies met the inclusion criteria, and 22 studies had the data necessary for a network meta-analysis. Relative effects show LLLT as the superior treatment. Relative effects show PRP, finasteride 1 mg (male), finasteride 1 mg (female), minoxidil 5%, minoxidil 2% and dutasteride (male) are approximately equivalent in mean change hair count following treatment. Minoxidil 5% and minoxidil 2% reported the most drug-related adverse events (n = 45 and n = 23, respectively). The quality of evidence of minoxidil 2% vs. minoxidil 5% was high; minoxidil 5% vs. placebo was moderate; dutasteride (male) vs. placebo, finasteride (female) vs. placebo, minoxidil 2% vs. placebo and minoxidil 5% vs. LLLT was low; and finasteride (male) vs. placebo, LLLT vs. sham, PRP vs. placebo and finasteride vs. minoxidil 2% was very low. Results of this NMA indicate the emergence of novel, non-hormonal therapies as effective treatments for hair loss; however, the quality of evidence is generally low. High-quality randomized controlled trials and head-to-head trials are required to support these findings and aid in the development of more standardized protocols, particularly for PRP. Regardless, this analysis may aid physicians in clinical decision-making and highlight the variety of non-surgical hair restoration options for patients.
Introduction
Androgenetic alopecia (AGA) is a common hair loss condition that is characterized by the miniaturization of hair follicles in the frontal and parietal regions of the scalp. 1 This miniaturization may be driven by the conversion of testosterone to dihydrotestosterone (DHT) by 5-a reductase or alterations in the androgen receptor gene. [2] [3] [4] Treatments, such as hormone and biological response modifiers, have been used to combat this miniaturization and stabilize hair loss in AGA patients. 5, 6 Hormone response modifiers, such as finasteride, promote hair growth by inhibiting type II 5-a reductase. This inhibition blocks the conversion of testosterone to DHT, promoting cell survival and proliferation. 5, 7 Although the exact mechanism for biological response modifiers, such as minoxidil, is not yet known, minoxidil is thought to promote hair growth through vasodilation and/or stimulation of hair follicles into the growth phase. [8] [9] [10] [11] As an alternative to traditional therapies, other nonsurgical treatments such as platelet-rich plasma (PRP) and lowlevel laser therapy (LLLT) have also shown promise. 12 Through isolating platelets found in whole blood, growth factors can be concentrated and injected into the hair follicle and surrounding area. Evidence has suggested that these concentrated growth factors can promote angiogenesis and vascularization, accelerate hair regrowth, increase the duration of the hair growth phase and stimulate catagen development. [13] [14] [15] [16] [17] Alternatively, through photobiomodulation, red light emitted by LLLT devices may encourage hair growth by accelerating keratinocyte and fibroblast mitosis, inhibiting nitric oxide and reducing inflammation [18] [19] [20] [21] ( Fig. 1a-d ).
Due to the limited number of head-to-head clinical trials and the limitations of published meta-analyses (e.g. comparisons limited to two treatments), comparing the efficacies of non-surgical treatments is predominately qualitative. 22 Quantitative comparisons of the efficacy of non-surgical AGA treatments that have not been directly compared in head-to-head trials would be a valuable tool for both clinicians and hair restoration surgeons, potentially aiding treatment decisions and influencing patient outcomes. To address this literature gap, a network meta-analysis was conducted using randomized control trials (RCTs) of six main non-surgical AGA treatments: finasteride, dutasteride, minoxidil (2% and 5%), PRP and LLLT. Using placebo as a common comparator, the efficacy of non-surgical treatments was indirectly and directly compared, using the mean difference in hair count from baseline as the outcome measure. 23 
Materials and methods

Systematic review
This systematic review and meta-analysis were conducted in agreement with the 2015 modified 32-item PRISMA extension statement for network meta-analysis (NMA). 24 Studies were eligible for inclusion if they were randomized, placebo-controlled or head-to-head trials of non-surgical treatment for androgenetic alopecia published in English. Combination therapies were not included. Details regarding the databases searched and study identification for this review are provided in Appendix S1 (see Supplementary Material). Treatment effects were evaluated based on the efficacy rates and safety parameters reported in the randomized trials identified during the systematic review. Hair count was selected as our primary outcome, and the end point selected was the most commonly reported time per treatment regime (Table S1 ). Details regarding the quality of evidence and risk-of- bias assessment for this review are provided in Appendix S1. 25 Data extracted from trials were combined by a random-effects model, with effect sizes expressed as difference of means of achieving each outcome in the treatment arm vs. the control arm. Total effect size was calculated by the Mantel-Haenszel method. Heterogeneity was evaluated with I 2 calculations. Statistical analysis was performed with RevMan 5.3 (http://tech.coc hrane.org/revman), with two-tailed P-values < 0.05 considered significant. Forest plots and funnel plots were obtained for each outcome analysed and included in the Appendix S1.
Network meta-analysis
Network meta-analysis was used to make mixed comparisons among the therapeutic options and to rank treatments, using the program Aggregate Data Drug Information Software (ADDIS) version 1.16.8 program. 26 Inconsistency between direct and indirect evidence in the network was analysed using difference of means. A P-value < 0.05 indicated significant inconsistency between the direct and indirect evidence in the network. (Table 1) . Twenty-two studies 28, 32, 37, 45, 46, 48, 52, 61, 64, 65, 68, 69, 72, 80, 81, 84, 85, 93, 98, [101] [102] [103] of the 78 included in the quantitative analysis had the data necessary for a network meta-analysis. The included trials had 2421 randomized participants, which were 64.2% male. The average age of participants was 37.7 AE 7.1. The severity of disease was most commonly IV (n = 273) and III vertex (n = 497) on the Norwood-Hamilton classification and II (n = 381) on the Ludwig/Savin Scale. Detailed information for all the studies included in the network meta-analysis is presented in Table 1 . A network graph summarizing the comparisons is provided in Fig. 3 .
Results
Results of the search
Risk of bias
None of the included studies were judged to be low-risk across all six domains ( Figure S1 ). (27%). Price et al. 84 was the only study to have an unclear judgement across all domains.
Quality of evidence
When considering mean hair count, evidence for treatment efficacy was generally low quality according to GRADEpro assessment. In treatment vs. placebo studies, LLLT, PRP and finasteride (male) reported very low quality of evidence, and finasteride (female), dutasteride (male) and minoxidil 2% had low-quality evidence and minoxidil 5% had moderate quality evidence. When considering the treatment vs. treatment, finasteride (male) vs. minoxidil 2% had very low-level quality of evidence, minoxidil 5% vs. LLLT had low level of evidence, and minoxidil 2% vs. minoxidil 5% had high quality of evidence.
Evidence was downgraded initially due to high risk of bias. Additionally, LLLT studies showed considerable inconsistency with high heterogeneity (I 2 = 93%). Dutasteride (male), LLLT, PRP, finasteride (male) vs minoxidil 2% and minoxidil 5% vs LLLT analysed less than 400 participants which contributed to the imprecision of the evidence.
Efficacy of direct comparisons
Meta-analysis of direct pairwise comparisons showed that all non-surgical treatments exhibited greater efficacy over placebo with response to mean change hair count ( Minoxidil 5% had the most drug-related adverse events (n = 45), whereas PRP had the least (n = 0) ( Tables 1 and 5 ). Direct comparisons of treatments showed that finasteride was favoured over minoxidil 2% (8. (Table 3) . Otherwise, relative effects showed that PRP, finasteride (male), finasteride (female), minoxidil 5%, minoxidil 2% and dutasteride (male) are approximately equivalent in mean change hair count following treatment (Table 3) .
Inconsistency analysis
The indirect comparison of minoxidil 5% vs. placebo, minoxidil 5% vs. minoxidil 2%, minoxidil 5% vs. LLLT and finasteride (male) vs. placebo showed a treatment effect larger than the direct evidence. The indirect comparisons of minoxidil 2% vs. placebo, LLLT vs. sham and minoxidil 2% vs. finasteride (male) showed a treatment effect smaller than the direct evidence (Table 4) .
Model fit
The mean deviance under the current model, relative to the deviance under a saturated model, is referred to as the residual deviance. The residual deviance of our model was 50.5, the leverage (the influence of each data point) was 42.8, and the deviance information criterion (model fit vs. model complexity) was 93.3. The number of data points on which the fit is based was 46 (Figure S6 ).
Ranking of treatments by efficacy
Rank probabilities encode the probability for each treatment to be the best, second best, third best, etc. The probability that LLLT will be the most effective treatment option (rank 1) for our data is 92%, followed by PRP (5.2%). The probability that PRP will be the second most effective treatment option (rank 2) is 33.8%, followed by minoxidil 5% (21.8%). The probability that finasteride (male) will be the third most effective treatment option is 29.3%, and so on (Fig. 4) .
We used the surface under the cumulative ranking (SUCRA) probabilities to assess the efficacy of treatments. SUCRA expresses a percentage representing the efficacy of every intervention compared with a control. It is used to provide a hierarchy of the treatments and accounts both for the location and the variance of all relative treatment effects. A higher SUCRA score indicates a higher probability to be effective. The SUCRA scores demonstrate LLLT with the highest SUCRA (98.7%) followed by PRP, finasteride (male) and minoxidil 5% with similar scores (64.3%, 62.5% and 62.4%, respectively). Minoxidil 2%, dutasteride (male) and finasteride (female) report lower scores (51.0%, 32.9% and 14.4%, respectively) ( Table 5) .
Discussion
This network meta-analysis (NMA) compared the relative efficacy of finasteride, minoxidil 2% and 5%, low-level laser therapy and platelet-rich plasma therapy in the treatment of androgenetic alopecia. Results indicate that the mean difference of LLLT is greater compared to all treatments. Additionally, relative effects show PRP, finasteride 1 mg, minoxidil 5%, minoxidil 2% and dutasteride are approximately equivalent in mean change hair count following treatment. Minoxidil 5% and 2% reported the greatest amount of adverse events.
While results of this NMA indicate LLLT produced the largest increase in hair count, the quality of evidence is very low as determined by the risk-of-bias assessment. Further, these trials may require further scrutiny, as all five trials included in the NMA report funding and support from the device manufacturer or funding and/or affiliation of the author with the manufacturer. Nonetheless, these trials met the strict inclusion criteria of this NMA and analysis indicates LLLT is a highly effective treatment option.
PRP is also an effective treatment for AGA. However, quality of evidence of PRP is 'very low' according to GRADEpro Non-surgical treatments for androgenetic alopecia assessment. There are few randomized controlled trials examining the efficacy of PRP in AGA. Half head studies are common in the literature; however, this design may be considered problematic as each patient contributes to the treatment and control arm of the study. There is also a high degree of variability in study design among PRP trials. Studies have reported treatment administration weekly, monthly, and bimonthly and range in the total number of treatment sessions. Further, unlike oral or topical formulations such as finasteride or minoxidil, which are prescribed at standard doses, there is significant variability in the preparation and administration of PRP. Individual preparation systems and added activators can influence the concentration of growth factors. 17 Coupled to variability in frequency and volume of injections, this creates substantial differences in dosing across studies. We included trials in which activated PRP was administered. Finasteride 1 mg and minoxidil 5% demonstrated similar efficacy. As such, other factors including the risk of adverse events (AEs) may contribute to clinical decision-making. AEs reported with finasteride use are predominantly related to sexual dysfunction. Decreased libido, erectile dysfunction and sexual adverse events are reported in several of the trials included in this NMA. The prevalence of sexual adverse events associated with finasteride use is widely discussed in the literature. We have previously demonstrated an increase in reports of sexual dysfunction with finasteride as the primary suspect in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). 104 Others report persistent sexual dysfunction up to 1 year after cessation of finasteride treatment. 105 The side-effects of minoxidil 5% ranged from dermatologic in nature, such as hypertrichosis, and burning and itching of the skin, to cardiovascular AEs. The mechanism of action of minoxidil may contribute to the cardiovascular AEs, as it is a vasodilator. While the results of this NMA indicate finasteride 1 mg and minoxidil 5% demonstrate similar efficacy, considering the AEs associated with each treatment may aid in clinical decision-making. We included data for male and female participants from trials for minoxidil, LLLT and PRP. However, we separated the males and females for finasteride and dutasteride as we felt the results would have been skewed if we combined them. There were no studies reporting females taking dutasteride. In AGA, dihydrotestosterone (DHT) binding to androgen receptors in the scalp contributes to hair loss. DHT is formed by enzymatic conversion of testosterone to DHT by 5a-reductase, and these enzymes are inhibited by finasteride and dutasteride. Given the hormonal mechanism of action of 5a-reductase inhibitors, they are not approved for the treatment of hair loss in female patients. Finasteride has been associated with negative effects on the fetus as well as menstrual and endometrial abnormalities among others. 106 Dutasteride is a dual 5a-reductase inhibitor, which is approved for use in the treatment of benign prostatic hyperplasia and is used off-label for hair loss. Therefore, data for female participants were separated from the males. A potential limitation of this analysis was the use of hair count as a primary outcome measure. AGA treatment efficacy can be determined with a variety of different assessments. Expert assessment of global photographs, hair counts using phototrichogram and manual hair counts using clippings has all been reported in the literature. Our rationale for selecting hair count was twofold: first, this is a more quantitative measure than global photographic assessment; studies reporting only global photographic assessment were not included. Figure 3 Network graph. The network graph shows the evidence network for all selected interventions. The size of an intervention's circle reflects the total number of participants for that intervention. Lines signify that interventions are connected through at least one study, with thicker lines indicating more connecting studies. Non-surgical treatments for androgenetic alopecia Second, some studies reported hair density (the number of hairs per predefined area). It is possible to convert hair count to hair density when provided a target area; however, it is not possible if the area is not specified. Therefore, to maximize the number of included trials in this NMA, we selected hair count as our primary outcome measure. Unfortunately, this may be a limiting factor, as larger target areas would in theory have greater hair counts. This presents a point of consideration in the development and initiation of new trials. The use of a consistent outcome measure may aid in the comparison of treatment efficacy across many different treatments for hair loss or other dermatological conditions. Another limitation of this study is the comparison of drugs with different routes of administration. Oral (finasteride), topical (LLLT, minoxidil) and intradermal injection (PRP) were all compared in this NMA. These treatments function through unique mechanisms of action and may have different metabolism and durations of effect. Despite this, all treatments compared in this analysis are FDA approved for use in the treatment of AGA. Therefore, these findings are relevant to clinicians and patients in the development of a treatment plan. A P value < 0.05 indicated significant inconsistency between the direct and indirect evidence in the network. *The P-value measures consistency by calculating the probability of observing the results from your sample of data or a sample with results more extreme, assuming the null hypothesis is true. The smaller the P-value, the greater the inconsistency. †The deviance information criterion (DIC) is a measure of model fit that penalizes model complexity. The DIC is used to compare fit between models for the same data; differences in DIC of 3 or greater are often considered relevant. 100 R a n k 1 R a n k 2 R a n k 3 R a n k 4 R a n k 5 R a n k 6 R a n k 7 R a n k Figure 4 Bar plots for the ranking probabilities of competing nonsurgical treatments for AGA. On the horizontal axis is the possible rank of each treatment (from best to worst according to the outcome). The size of each bar corresponds to the probability of each treatment to be at a specific rank. In addition to these limitations, the measurement of efficacy for AGA treatments has not yet been standardized; leading to multiple units of analysis reported across studies and therapies (e.g. hair density, hair count and hair shedding). Furthermore, of the 20 studies included in the analysis, only six (30%) did not have obvious links to industry. 28, 38, 45, 80, 93, 102 Most studies included in the analysis (14/ 20 = 70%) were supported or funded by invested parties (e.g. drug manufacturer and patent owner). This may have contributed to the high number of studies judged to have a high risk of reporting bias and/or attrition bias. Industry funding for studies is often inevitable and appreciated; high-quality trials with low risk of bias counter perceptions of conflicted interests. Systematic reviews as well as clinical trials must be designed rigorously to ensure the validity of the findings of the network meta-analysis. Interpreting the results of a NMA can prove challenging for the non-expert statistician. One of the most commonly misinterpreted parts of a NMA is the probability rankings. Ranking done in medical statistics will always depend on the criteria; one treatment may be best for efficacy but worse for long-term safety. A risk subsists that one may incorrectly accentuate the probabilities as being clinically useful. That is why it is important to consider the numerical values of the rankings themselves, not only their probability ranks. The SUCRA scores also can be misleading as the SUCRA is most meaningful when the difference in preference between successive ranks remains the same across the entire ranking scale. 107 Our data do not have such interval scaling, thus weakening the SUCRA evidence. For clinical application, greater emphasis on the treatment effects and their uncertainty are crucial. As new trials are published, the network will expand and treatment rankings may change considerably. Consideration should also be issued to cost and a clinician's familiarity with use of a particular treatment. In summary, results of this NMA indicate the emergence of more novel, non-hormonal therapies as effective treatments for hair loss. Further randomized controlled trials and head-to-head trials limiting risk of bias are required to support these findings and aid in the development of more standardized protocols, particularly for PRP. The data may provide guidance to physicians when counselling patients with AGA regarding non-surgical options.
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